WO2000042201A3 - Human peptidases - Google Patents

Human peptidases Download PDF

Info

Publication number
WO2000042201A3
WO2000042201A3 PCT/US2000/000641 US0000641W WO0042201A3 WO 2000042201 A3 WO2000042201 A3 WO 2000042201A3 US 0000641 W US0000641 W US 0000641W WO 0042201 A3 WO0042201 A3 WO 0042201A3
Authority
WO
WIPO (PCT)
Prior art keywords
hpep
provides
peptidases
human
human peptidases
Prior art date
Application number
PCT/US2000/000641
Other languages
French (fr)
Other versions
WO2000042201A2 (en
Inventor
Olga Bandman
Jennifer L Hillman
Y Tom Tang
Yalda Azimzai
Mariah R Baughn
Preeti Lal
Henry Yue
Dyung Aina M Lu
Original Assignee
Incyte Pharma Inc
Olga Bandman
Jennifer L Hillman
Y Tom Tang
Yalda Azimzai
Mariah R Baughn
Preeti Lal
Henry Yue
Dyung Aina M Lu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharma Inc, Olga Bandman, Jennifer L Hillman, Y Tom Tang, Yalda Azimzai, Mariah R Baughn, Preeti Lal, Henry Yue, Dyung Aina M Lu filed Critical Incyte Pharma Inc
Priority to CA002360464A priority Critical patent/CA2360464A1/en
Priority to AU25012/00A priority patent/AU2501200A/en
Priority to EP00903235A priority patent/EP1151113A2/en
Priority to JP2000593758A priority patent/JP2003532372A/en
Publication of WO2000042201A2 publication Critical patent/WO2000042201A2/en
Publication of WO2000042201A3 publication Critical patent/WO2000042201A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides human peptidases (HPEP) and polynucleotides which identify and encode HPEP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HPEP.
PCT/US2000/000641 1999-01-11 2000-01-11 Human peptidases WO2000042201A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002360464A CA2360464A1 (en) 1999-01-11 2000-01-11 Human peptidases
AU25012/00A AU2501200A (en) 1999-01-11 2000-01-11 Human peptidases
EP00903235A EP1151113A2 (en) 1999-01-11 2000-01-11 Human peptidases
JP2000593758A JP2003532372A (en) 1999-01-11 2000-01-11 Human peptidase

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17224799P 1999-01-11 1999-01-11
US60/172,247 1999-01-11
US13225399P 1999-05-03 1999-05-03
US60/132,253 1999-05-03
US13665399P 1999-05-27 1999-05-27
US60/136,653 1999-05-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09889238 A-371-Of-International 2002-01-24
US10/729,807 Division US20040132158A1 (en) 1999-01-11 2003-12-05 Human peptidases

Publications (2)

Publication Number Publication Date
WO2000042201A2 WO2000042201A2 (en) 2000-07-20
WO2000042201A3 true WO2000042201A3 (en) 2000-11-30

Family

ID=27384262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000641 WO2000042201A2 (en) 1999-01-11 2000-01-11 Human peptidases

Country Status (5)

Country Link
EP (1) EP1151113A2 (en)
JP (1) JP2003532372A (en)
AU (1) AU2501200A (en)
CA (1) CA2360464A1 (en)
WO (1) WO2000042201A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6369210B1 (en) 1999-06-30 2002-04-09 Millennium Pharmaceuticals, Inc. 22012, human carboxypeptidase
EP1218392A4 (en) * 1999-09-10 2003-04-09 Millennium Pharm Inc Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
EP1887082A3 (en) * 1999-10-20 2008-06-11 The Board Of Trustees Of The University Of Arkansas TADG-15: An extracellular serine protease overexpressed in carcinomas
US20020156005A1 (en) * 2000-09-25 2002-10-24 Meyers Rachel E. m32404, a novel human trypsin and uses thereof
US20020037827A1 (en) * 2000-03-06 2002-03-28 Kai Wang Novel matrix metalloproteinase (MMP-25) expressed in skin cells
HUP0301356A3 (en) * 2000-10-12 2010-03-29 Ferring Bv Novel serine protease genes related to dppiv
AUPR107800A0 (en) * 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
EP1545591A2 (en) * 2001-01-18 2005-06-29 Eli Lilly And Company Therapeutic use for lp229, in particular for wound healing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09149790A (en) * 1995-09-29 1997-06-10 Suntory Ltd New serine protease
WO1999042120A1 (en) * 1998-02-20 1999-08-26 The Board Of Trustees Of The University Of Arkansas Tadg-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09149790A (en) * 1995-09-29 1997-06-10 Suntory Ltd New serine protease
WO1999042120A1 (en) * 1998-02-20 1999-08-26 The Board Of Trustees Of The University Of Arkansas Tadg-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EMBL Database SEQ.ID. W22987 08 October 1997 Human serine protease 67, derived from human colon carcinoma COLO21 *
LIN C-Y ET AL: "Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 14, 4 April 1997 (1997-04-04), MD US, pages 9147 - 9152, XP002139962 *
LIN C-Y ET AL: "Molecular cloning of cDNA for Matriptase, a matrix-degrading serine protease with trypsin-like activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 26, 25 June 1999 (1999-06-25), MD US, pages 8231 - 18236, XP002139963 *
O'BRIEN ET AL.: "Cloning and expression of TADG-15, a novel serine protease expressed in ovarian cancer", TUMOR BIOLOGY, vol. 19, no. supplement 2, August 1998 (1998-08-01), pages 33, XP000914639 *
TAKEUCHI T ET AL.: "Reverse biochemistry: Use of macromlecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 96, 28 September 1999 (1999-09-28), WASHINGTON US, pages 11054 - 11061, XP002139964 *
TANIMOTO H ET AL: "Cloning and expression of TADG-15, a novel serine protease expressed in ovarian cancer", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 39, March 1998 (1998-03-01), pages 648, XP000914623 *

Also Published As

Publication number Publication date
WO2000042201A2 (en) 2000-07-20
JP2003532372A (en) 2003-11-05
CA2360464A1 (en) 2000-07-20
EP1151113A2 (en) 2001-11-07
AU2501200A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
WO2001012662A3 (en) Membrane associated proteins
WO1999036550A3 (en) Human protease molecules
WO2001007628A3 (en) Human synthetases
WO2000018922A3 (en) Human carbohydrate-associated proteins
WO2000034477A3 (en) Neuron-associated proteins
WO1999058692A3 (en) Human apoptosis associated proteins
WO2000009709A3 (en) Proteases and associated proteins
WO2000078953A3 (en) Human transport proteins
WO2000052151A3 (en) Human secretory proteins
WO2001072777A3 (en) Human transcription factors
WO2000000594A3 (en) Human transferases
WO2001044448A3 (en) Human oxidoreductase proteins
WO2000042201A3 (en) Human peptidases
WO2000020604A3 (en) Oxidoreductase molecules
WO2001032888A3 (en) Human transferase molecules
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2000028045A3 (en) Human hydrolase proteins
WO1999041373A3 (en) Human transport-associated molecules
WO2001071004A3 (en) Proteases
WO2000065054A3 (en) Human membrane-associated proteins
WO2000078954A3 (en) Human transcriptional regulator proteins
WO2001046443A3 (en) Proteases
WO2002026998A3 (en) Hydrolases
WO2000001821A3 (en) Neurotransmission associated proteins
WO2000024911A3 (en) Human phospholipases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000903235

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2360464

Country of ref document: CA

Ref country code: CA

Ref document number: 2360464

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 593758

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000903235

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09889238

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000903235

Country of ref document: EP